Feifan Yao

Key Laboratory Of Liver Transplantation, Key Laboratory Of Hepatobiliary Tumors, Jiangsu Provincial Medical Key Laboratory
Nanjing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Glutathione peroxidase 3 preserves hepatocyte mitochondrial quality control to enhance macrophage pro-regenerative phenotype during liver regeneration.

Glutathione peroxidase 3 preserves hepatocyte mitochondrial quality control to enhance macrophage pro-regenerative phenotype during liver regeneration.

Journal: Clinical and translational medicine

Published: January 07, 2026

JOSD1 drives hepatocellular carcinoma malignancy by modulating the ubiquitination-lactylation switch on PGAM1.

JOSD1 drives hepatocellular carcinoma malignancy by modulating the ubiquitination-lactylation switch on PGAM1.

Journal: Gut

Published: October 20, 2025

Landscape screening identifies the lactate-modifying enzyme AARS2 as a master regulator and therapeutic target in hepatocellular carcinoma.

Landscape screening identifies the lactate-modifying enzyme AARS2 as a master regulator and therapeutic target in hepatocellular carcinoma.

Journal: Gut

Published: October 20, 2025

Ciprofol exerts anti-tumour effects in hepatocellular carcinoma through the Raf-MEK-ERK signalling pathway.

Ciprofol exerts anti-tumour effects in hepatocellular carcinoma through the Raf-MEK-ERK signalling pathway.

Journal: Translational gastroenterology and hepatology

Published: September 19, 2024

eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma.

eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma.

Journal: Journal of hepatology

Published: July 02, 2024

CRISPR/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma.

CRISPR/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma.

Journal: Cancer letters

Published: December 12, 2023

Hepatocyte Deubiquitinating Enzyme OTUD5 Deficiency is a Key Aggravator for Metabolic Dysfunction-Associated Steatohepatitis by Disturbing Mitochondrial Homeostasis.

Hepatocyte Deubiquitinating Enzyme OTUD5 Deficiency is a Key Aggravator for Metabolic Dysfunction-Associated Steatohepatitis by Disturbing Mitochondrial Homeostasis.

Journal: Cellular and molecular gastroenterology and hepatology

Published: August 12, 2023

Hypomethylation-enhanced CRTC2 expression drives malignant phenotypes and primary resistance to immunotherapy in hepatocellular carcinoma.

Hypomethylation-enhanced CRTC2 expression drives malignant phenotypes and primary resistance to immunotherapy in hepatocellular carcinoma.

Journal: iScience

Published: July 19, 2023

Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.

Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.

Journal: Journal of hepatology

Published: March 23, 2023

Etomidate elicits anti-tumor capacity by disrupting the JAK2/STAT3 signaling pathway in hepatocellular carcinoma.

Etomidate elicits anti-tumor capacity by disrupting the JAK2/STAT3 signaling pathway in hepatocellular carcinoma.

Journal: Cancer letters

Published: July 26, 2022

Thymidine kinase 1 drives hepatocellular carcinoma in enzyme-dependent and -independent manners.

Thymidine kinase 1 drives hepatocellular carcinoma in enzyme-dependent and -independent manners.

Journal: Cell metabolism

Published: September 28, 2021

PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells.

PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells.

Journal: Nature communications

Published: July 23, 2021

Showing 1-12 of 12

Last Updated: 09/26/2026